DAG181
Showing 1 - 9 of 9
Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic, Cirrhosis Trial in Beijing (non-cirrhotic subjects. low TG-2349+ low
Completed
- Chronic Hepatics C Virus (HCV) Genotype 1
- +3 more
- non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin
- +5 more
-
Beijing, Beijing, ChinaPeking University Peoples Hospital
Feb 16, 2021
Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic, Cirrhosis Trial in Beijing (TG-2349, DAG181, Ribavirin)
Completed
- Chronic Hepatics C Virus (HCV) Genotype 1
- +3 more
- TG-2349
- +2 more
-
Beijing, ChinaBeijing Tsinghua Changgung Hospital
Feb 2, 2021
Renal Impairment Trial in Chengdu (Yimitasvir Phosphate Capsule)
Recruiting
- Renal Impairment
- Yimitasvir Phosphate Capsule
-
Chengdu, Sichuan, ChinaWest China Hospital of Sichuan University
May 6, 2021
Healthy Chinese Volunteers Trial in Changsha (TG-2349 (400 mg) plus DAG181 (200 mg), DAG181 (200 mg) plus TG-2349 (400 mg))
Completed
- Healthy Chinese Volunteers
- TG-2349 (400 mg) plus DAG181 (200 mg)
- DAG181 (200 mg) plus TG-2349 (400 mg)
-
Changsha, Hunan, ChinaXiangya Hospital Central South University
Jul 26, 2018
Chronic Hepatitis c Trial in Beijing (yimitasvir, )
Completed
- Chronic Hepatitis c
- yimitasvir
- placebo
-
Beijing, Beijing, ChinaPeking University First Hospital
Mar 8, 2018
COPD - COPD, Muscle Atrophy Trial in Frederikssund (Intervention-training-group)
Withdrawn
- COPD - Chronic Obstructive Pulmonary Disease
- Muscle Atrophy
- Intervention-training-group
-
Frederikssund, DenmarkFrederikssund Hospital
Oct 25, 2013
Clinical Course of Diabetic Nephropathy: Population-Based Study
Unknown status
- Diabetes
- +2 more
- Rosiglitasone (retrospective observation)
-
Zerifin,, IsraelClalit Health Cervices, Central District
Jul 6, 2007